Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.412
Filter
Add more filters

Publication year range
1.
Toxicol Appl Pharmacol ; 484: 116881, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38437958

ABSTRACT

Pain has a negative impact on public health, reducing quality of life. Unfortunately, current treatments are not fully effective and have adverse effects. Therefore, there is a need to develop new analgesic compounds. Due to promising results regarding the antinociceptive effect of N-(3-(phenylselanyl)prop-2-in-1-yl)benzamide (SePB), this study aimed to evaluate the participation of the dopaminergic and noradrenergic systems in this effect in mice, as well as its toxicity. To this, the antagonists sulpiride (D2/D3 receptor antagonist, 5 mg/kg), SCH-23390 (D1 receptor antagonist, 0.05 mg/kg), prazosin (α1 adrenergic receptor antagonist, 0.15 mg/kg), yohimbine (α2-adrenergic receptors, 0.15 mg/kg) and propranolol (non-selective ß-adrenergic antagonist, 10 mg/kg) were administered intraperitoneally to mice 15 min before SePB (10 mg/kg, intragastrically), except for propranolol (20 min). After 26 min of SePB administration, the open field test was performed for 4 min to assess locomotor activity, followed by the tail immersion test to measure the nociceptive response. For the toxicity test, animals received a high dose of 300 mg/kg of SePB. SePB showed an increase in the latency for nociceptive response in the tail immersion test, and this effect was prevented by SCH-23390, yohimbine and propranolol, indicating the involvement of D1, α2 and ß-adrenergic receptors in the antinociceptive mechanism of the SePB effect. No changes were observed in the open field test, and the toxicity assessment suggested that SePB has low potential to induce toxicity. These findings contribute to understanding SePB's mechanism of action, with a focus on the development of new alternatives for pain treatment.


Subject(s)
Propranolol , Quality of Life , Mice , Animals , Propranolol/pharmacology , Propranolol/therapeutic use , Analgesics/toxicity , Pain/drug therapy , Norepinephrine , Yohimbine/toxicity , Yohimbine/therapeutic use , Adrenergic alpha-1 Receptor Antagonists/therapeutic use , Dopamine , Sulpiride , Receptors, Adrenergic, alpha-2
2.
Zhongguo Zhong Yao Za Zhi ; 48(1): 220-225, 2023 Jan.
Article in Chinese | MEDLINE | ID: mdl-36725274

ABSTRACT

This paper aimed to investigate the effect of total flavonoids of buckwheat flower and leaf on myocardial cell apoptosis and Wnt/ß-catenin/peroxisome proliferator-activated receptor γ(PPARγ) pathway in arrhythmic rats. SD rats were randomly divided into a control group, a model group, a low-dose(20 mg·kg~(-1)) group of total flavonoids of buckwheat flower and leaf, a medium-dose(40 mg·kg~(-1)) group of total flavonoids of buckwheat flower and leaf, a high-dose(80 mg·kg~(-1)) group of total flavonoids of buckwheat flower and leaf, a propranolol hydrochloride(2 mg·kg~(-1)) group, with 12 rats in each group. Except the control group, rats in other groups were prepared as models of arrhythmia by sublingual injection of 1 mL·kg~(-1) of 0.002% aconitine. After grouping and intervention with drugs, the arrhythmia, myocardial cells apoptosis, myocardial tissue glutathione peroxidase(GSH-Px), catalase(CAT), malondialdehyde(MDA), serum interleukin-6(IL-6), prostaglandin E2(PGE2) levels, myocardial tissue apoptosis, and Wnt/ß-catenin/PPARγ pathway-related protein expression of rats in each group were measured. As compared with the control group, the arrhythmia score, the number of ventricular premature beats, ventricular fibrillation duration, myocardial cell apoptosis rate, MDA levels in myocardial tissues, serum IL-6 and PGE2 levels, Bax in myocardial tissues, and Wnt1 and ß-catenin protein expression levels increased significantly in the model group, whereas the GSH-Px and CAT levels, and Bcl-2 and PPARγ protein expression levels in myocardial tissues reduced significantly. As compared with the model group, the arrhythmia score, the number of ventricular premature beats, ventricular fibrillation duration, myocardial cell apoptosis rate, MDA leve in myocardial tissues, serum IL-6 and PGE2 levels, Bax in myocardial tissues, and Wnt1 and ß-catenin protein expression levels reduced in the drug intervention groups, whereas the GSH-Px and CAT levels and Bcl-2 and PPARγ protein expression levels in myocardial tissues increased. The groups of total flavonoids of buckwheat flower and leaf were in a dose-dependent manner. There was no significant difference in the levels of each index in rats between the propranolol hydrochloride group and the high-dose group of total flavonoids of buckwheat flower and leaf. The total flavonoids of buckwheat flower and leaf inhibit the activation of Wnt/ß-catenin pathway, up-regulate the expression of PPARγ, reduce oxidative stress and inflammatory damage in myocardial tissues of arrhythmic rats, reduce myocardial cell apoptosis, and improve the symptoms of arrhythmia in rats.


Subject(s)
Fagopyrum , PPAR gamma , Rats , Animals , PPAR gamma/metabolism , Fagopyrum/genetics , Rats, Sprague-Dawley , bcl-2-Associated X Protein , beta Catenin/genetics , beta Catenin/metabolism , Interleukin-6 , Flavonoids/pharmacology , Propranolol/pharmacology , Ventricular Fibrillation , Dinoprostone , Wnt Signaling Pathway , Plant Leaves/metabolism , Flowers/metabolism , Apoptosis , Cardiac Complexes, Premature
3.
Altern Ther Health Med ; 29(3): 262-265, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36634316

ABSTRACT

Background: Adults with hyperthyroidism have been found to have decreased bone mineral density (BMD) and higher fracture risk. The most typical cause of hyperthyroidism is Graves' disease. However, there are limited studies on how hyperthyroidism affects bone metabolism and fractures in children. We describe a unique instance of a patient who initially displayed a fragility fracture and was ultimately identified with Graves' disease after biochemical evaluations. Case Summary: A 2-year-8-month-old female presented with fragility fractures three times in only 7 months. A series of examinations were performed to evaluate any possible malformations or abnormalities of bone metabolism. Graves' disease was found, and drug therapies were employed (methimazole, propranolol, calcium carbonate, vitamin D). Since children with Graves' disease and fragility fractures have been uncommonly described in the past, a stringent and thorough long-term follow-up was initiated. Conclusions: Children with undiagnosed Graves' disease had a higher risk of fractures and osteoporosis. This case suggests that BMD measurement may be necessary for the initial evaluation of Graves' disease in children.


Subject(s)
Graves Disease , Hyperthyroidism , Osteoporosis , Adult , Female , Child , Humans , Infant , Graves Disease/complications , Graves Disease/diagnosis , Graves Disease/drug therapy , Methimazole/therapeutic use , Osteoporosis/drug therapy , Propranolol/therapeutic use , Hyperthyroidism/drug therapy
4.
Article in Chinese | WPRIM | ID: wpr-970517

ABSTRACT

This paper aimed to investigate the effect of total flavonoids of buckwheat flower and leaf on myocardial cell apoptosis and Wnt/β-catenin/peroxisome proliferator-activated receptor γ(PPARγ) pathway in arrhythmic rats. SD rats were randomly divided into a control group, a model group, a low-dose(20 mg·kg~(-1)) group of total flavonoids of buckwheat flower and leaf, a medium-dose(40 mg·kg~(-1)) group of total flavonoids of buckwheat flower and leaf, a high-dose(80 mg·kg~(-1)) group of total flavonoids of buckwheat flower and leaf, a propranolol hydrochloride(2 mg·kg~(-1)) group, with 12 rats in each group. Except the control group, rats in other groups were prepared as models of arrhythmia by sublingual injection of 1 mL·kg~(-1) of 0.002% aconitine. After grouping and intervention with drugs, the arrhythmia, myocardial cells apoptosis, myocardial tissue glutathione peroxidase(GSH-Px), catalase(CAT), malondialdehyde(MDA), serum interleukin-6(IL-6), prostaglandin E2(PGE2) levels, myocardial tissue apoptosis, and Wnt/β-catenin/PPARγ pathway-related protein expression of rats in each group were measured. As compared with the control group, the arrhythmia score, the number of ventricular premature beats, ventricular fibrillation duration, myocardial cell apoptosis rate, MDA levels in myocardial tissues, serum IL-6 and PGE2 levels, Bax in myocardial tissues, and Wnt1 and β-catenin protein expression levels increased significantly in the model group, whereas the GSH-Px and CAT levels, and Bcl-2 and PPARγ protein expression levels in myocardial tissues reduced significantly. As compared with the model group, the arrhythmia score, the number of ventricular premature beats, ventricular fibrillation duration, myocardial cell apoptosis rate, MDA leve in myocardial tissues, serum IL-6 and PGE2 levels, Bax in myocardial tissues, and Wnt1 and β-catenin protein expression levels reduced in the drug intervention groups, whereas the GSH-Px and CAT levels and Bcl-2 and PPARγ protein expression levels in myocardial tissues increased. The groups of total flavonoids of buckwheat flower and leaf were in a dose-dependent manner. There was no significant difference in the levels of each index in rats between the propranolol hydrochloride group and the high-dose group of total flavonoids of buckwheat flower and leaf. The total flavonoids of buckwheat flower and leaf inhibit the activation of Wnt/β-catenin pathway, up-regulate the expression of PPARγ, reduce oxidative stress and inflammatory damage in myocardial tissues of arrhythmic rats, reduce myocardial cell apoptosis, and improve the symptoms of arrhythmia in rats.


Subject(s)
Rats , Animals , PPAR gamma/metabolism , Fagopyrum/genetics , Rats, Sprague-Dawley , bcl-2-Associated X Protein , beta Catenin/metabolism , Interleukin-6 , Flavonoids/pharmacology , Propranolol/pharmacology , Ventricular Fibrillation , Dinoprostone , Wnt Signaling Pathway , Plant Leaves/metabolism , Flowers/metabolism , Apoptosis , Cardiac Complexes, Premature
5.
Medicina (Kaunas) ; 58(9)2022 Sep 07.
Article in English | MEDLINE | ID: mdl-36143915

ABSTRACT

Over the last years, repurposed agents have provided growing evidence of fast implementation in oncology treatment such as certain antimalarial, anthelmintic, antibiotics, anti-inflammatory, antihypertensive, antihyperlipidemic, antidiabetic agents. In this study, the four agents of choice were present in our patients' daily treatment for nonmalignant-associated pathology and have known, light toxicity profiles. It is quite common for a given patient's daily administration schedule to include two or three of these drugs for the duration of their treatment. We chose to review the latest literature concerning metformin, employed as a first-line treatment for type 2 diabetes; mebendazole, as an anthelmintic; atorvastatin, as a cholesterol-lowering drug; propranolol, used in cardiovascular diseases as a nonspecific inhibitor of beta-1 and beta-2 adrenergic receptors. At the same time, certain key action mechanisms make them feasible antitumor agents such as for mitochondrial ETC inhibition, activation of the enzyme adenosine monophosphate-activated protein kinase, amelioration of endogenous hyperinsulinemia, inhibition of selective tyrosine kinases (i.e., VEGFR2, TNIK, and BRAF), and mevalonate pathway inhibition. Despite the abundance of results from in vitro and in vivo studies, the only solid data from randomized clinical trials confirm metformin-related oncological benefits for only a small subset of nondiabetic patients with HER2-positive breast cancer and early-stage colorectal cancer. At the same time, clinical studies confirm metformin-related detrimental/lack of an effect for lung, breast, prostate cancer, and glioblastoma. For atorvastatin we see a clinical oncological benefit in patients and head and neck cancer, with a trend towards radioprotection of critical structures, thus supporting the role of atorvastatin as a promising agent for concomitant association with radiotherapy. Propranolol-related increased outcomes were seen in clinical studies in patients with melanoma, breast cancer, and sarcoma.


Subject(s)
Anthelmintics , Antimalarials , Antineoplastic Agents , Breast Neoplasms , Diabetes Mellitus, Type 2 , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Metformin , Adenosine Monophosphate/therapeutic use , Adrenergic beta-Antagonists/therapeutic use , Anthelmintics/therapeutic use , Anti-Bacterial Agents/therapeutic use , Antihypertensive Agents/therapeutic use , Antimalarials/therapeutic use , Antineoplastic Agents/therapeutic use , Atorvastatin/therapeutic use , Breast Neoplasms/pathology , Cholesterol , Diabetes Mellitus, Type 2/drug therapy , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypoglycemic Agents/therapeutic use , Male , Mebendazole/therapeutic use , Metformin/therapeutic use , Mevalonic Acid/therapeutic use , Propranolol/therapeutic use , Protein Kinases/metabolism , Protein Kinases/therapeutic use , Proto-Oncogene Proteins B-raf , Receptors, Adrenergic, beta-2/therapeutic use , Tyrosine
6.
Exp Neurol ; 358: 114210, 2022 12.
Article in English | MEDLINE | ID: mdl-36007599

ABSTRACT

Essential tremor (ET) is the most frequent form of pathologic tremor and one of the most common adult-onset neurologic impairments. However, underlying mechanisms by which structural alterations within the tremor circuit generate the pathological state and how rhythmic neuronal activities propagate and drive tremor remains unclear. Harmaline (HA)-induced tremor model has been most frequently utilized animal model for ET studies, however, there is still a dearth of knowledge over the degree to whether HA-induced tremor mimics the actual underlying pathophysiology of ET, particularly the involvement of thalamo-cortical region. In this study, we investigated the electrophysiological response of the motor circuit including the ventrolateral thalamus (vlTh) and the primary motor cortex (M1), and the modulatory effect of thalamic deep brain stimulation (DBS) using a rat HA-induced tremor model. We found that the theta and high-frequency oscillation (HFO) band power significantly increased after HA administration in both vlTh and M1, and the activity was modulated by the tremor suppression drug (propranolol) and the thalamic DBS. The theta band phase synchronization between the vlTh and M1 was significantly enhanced during the HA-induced tremor, and the transition of cross-frequency coupling in vlTh was found to be associated with the state of HA-induced tremor. Our findings support that the HA tremor could be useful as a valid preclinical model of ET in the context of thalamo-cortical neural network interaction.


Subject(s)
Deep Brain Stimulation , Essential Tremor , Motor Cortex , Animals , Essential Tremor/chemically induced , Essential Tremor/therapy , Harmaline/toxicity , Motor Cortex/pathology , Propranolol , Rats , Rodentia , Thalamus/pathology , Tremor/chemically induced
7.
PLoS One ; 17(8): e0271442, 2022.
Article in English | MEDLINE | ID: mdl-36018842

ABSTRACT

Propranolol hydrochloride is a beta-blocker used for the management and treatment of hypertension, angina, coronary artery disease, heart failure, fibrillation, tremors, migraine etc. The objective of the present study was to design Propranolol Hydrochloride floating tablets by direct compression method and to explore the role of a new gum as a matrix former. A 22 full factorial design was selected for the present study. Prunus domestica gum and HPMC (K4M) were used as independent variables, swelling index and drug dissolution at 12 hours as dependent variables. Formulations were subjected to pre- and post-compression tests that showed good micromeritics and buoyancy characteristics (Carr's index 11.76%-14.00%, Hausner's ratio 1.13°-1.16°, angle of repose 22.67°-25.21°, floating lag time 56-76 seconds, total floating time 18-25 hours and swelling index 59.87%-139.66%). The cumulative drug release in 0.1 N HCl at 12 hours was 72%-90% (p<0.05). Weibull model was found to be the best fit model (R2>0.99) among all other studied models. Multiple regression showed a significant effect of Prunus domestica gum and HPMC K4M on the swelling index and dissolution profiles of propranolol HCl (p<0.05). On the basis of better in-vitro performance and cost-effectiveness, formulation F4 was the best formulation. It is evident from the results that Prunus domestica gum possesses excellent drug release retardant potential for the floating drug delivery system and this new gum should be further explored alone or with other natural and synthetic polymers in future studies.


Subject(s)
Propranolol , Prunus domestica , Delayed-Action Preparations , Drug Delivery Systems , Drug Liberation , Tablets
8.
Biomarkers ; 27(5): 488-495, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35400254

ABSTRACT

BACKGROUND: The cardio-protective effects of Terminalia catappa and Terminalia chebula are well-recognized in Ayurveda for its antimicrobial, antidiabetic and antioxidant potentials. The present study evaluates the effects of T. catappa leaves (Tct.LE) and T. chebula fruits (Tce.FE) against doxorubicin (DOX)-induced rats through analysis of the cardiac biomarkers, tricarboxylic acid (TCA) cycle enzymes and respiratory chain enzymes for their cardio-protective properties. MATERIALS AND METHODS: This study includes 42 adult male Albino Wistar rats randomized into seven groups for 21-days. Groups were categorized as control; DOX (1.5 mg/kg) induced negative control; basal diet with 300 mg/kg of Tct.LE, with 300 mg/kg Tce.FE; DOX with 300 mg/kg of Tct.LE, Tce.FE, and propranolol (25 mg/kg). RESULTS AND DISCUSSION: The doses of 300 mg/kg of both plants have a significant effect on the TCA cycle, respiratory and lysosomal enzymes activity. The troponin levels are significantly reduced in plant treated group than the DOX-treated rats when compared with the control and propranolol treated group. Likewise, the increased level of creatine kinase-muscle/MB, creatine kinase and lipid profile in the DOX-treated animals were significantly reduced upon being treated with extracts. CONCLUSION: The cardio-protective activity of Tct.LE leaves and Tce.FE indicate its potential use in the management of cardiovascular diseases.


Subject(s)
Cardiomyopathies , Terminalia , Animals , Cardiomyopathies/chemically induced , Cardiomyopathies/drug therapy , Cardiomyopathies/prevention & control , Creatine Kinase , Doxorubicin/adverse effects , Fruit , Male , Plant Extracts/chemistry , Plant Extracts/pharmacology , Propranolol , Rats , Rats, Wistar , Terminalia/chemistry
9.
J Bone Miner Res ; 37(5): 954-971, 2022 05.
Article in English | MEDLINE | ID: mdl-35122666

ABSTRACT

Although the nonselective ß-blocker, propranolol, improves bone density with parathyroid hormone (PTH) treatment in mice, the mechanism of this effect is unclear. To address this, we used a combination of in vitro and in vivo approaches to address how propranolol influences bone remodeling in the context of PTH treatment. In female C57BL/6J mice, intermittent PTH and propranolol administration had complementary effects in the trabecular bone of the distal femur and fifth lumbar vertebra (L5 ), with combination treatment achieving microarchitectural parameters beyond that of PTH alone. Combined treatment improved the serum bone formation marker, procollagen type 1 N propeptide (P1NP), but did not impact other histomorphometric parameters relating to osteoblast function at the L5 . In vitro, propranolol amplified the acute, PTH-induced, intracellular calcium signal in osteoblast-like cells. The most striking finding, however, was suppression of PTH-induced bone resorption. Despite this, PTH-induced receptor activator of nuclear factor κ-B ligand (RANKL) mRNA and protein levels were unaltered by propranolol, which led us to hypothesize that propranolol could act directly on osteoclasts. Using in situ methods, we found Adrb2 expression in osteoclasts in vivo, suggesting ß-blockers may directly impact osteoclasts. Consistent with this, we found propranolol directly suppresses osteoclast differentiation in vitro. Taken together, this work suggests a strong anti-osteoclastic effect of nonselective ß-blockers in vivo, indicating that combining propranolol with PTH could be beneficial to patients with extremely low bone density. © 2022 American Society for Bone and Mineral Research (ASBMR).


Subject(s)
Bone Resorption , Parathyroid Hormone , Animals , Bone Resorption/drug therapy , Bone Resorption/metabolism , Bone and Bones , Female , Humans , Mice , Mice, Inbred C57BL , Osteoblasts , Osteoclasts/metabolism , Osteogenesis , Parathyroid Hormone/metabolism , Parathyroid Hormone/pharmacology , Propranolol/metabolism , Propranolol/pharmacology
10.
J Complement Integr Med ; 19(2): 287-296, 2022 Jun 01.
Article in English | MEDLINE | ID: mdl-34323061

ABSTRACT

OBJECTIVES: To investigate effect of beta adrenergic blockade on intestinal lactate production and glycogen concentration in dogs infused with hexoses. METHODS: Experiments were carried out on 35 fasted male anaesthetized dogs weighing between 9 and 16 kg. The animals were divided into 7 (5 dogs per group) groups. Group I dogs served as control and infused with normal saline, groups II-IV were intravenously infused with glucose (1.1 mg/kg/min), fructose (1.1 mg/kg/min) and galactose (1.1 mg/kg/min) respectively while groups V-VII animals were pretreated with propranolol (0.5 mg/kg) and were infused with glucose, fructose or galactose respectively. A vein draining the proximal segment of the jejunum was cannulated along with right and left femoral arteries and veins. Glucose uptake was calculated as the product of jejunal blood flow and the difference between arterial and venous glucose levels (A-V glucose), part of the jejunum tissue was homogenized for estimation of glycogen concentration, and plasma lactate was assayed using lactate colorimetric kit. RESULTS: The result showed significant increase in venous lactate production in response to glucose (78.30 ± 4.57 mg/dL), fructose (60.72 ± 1.82 mg/dL) and galactose (71.70 ± 1.30 mg/dL) when compared with the control group (51.75 ± 1.32 mg/dL) at (p<0.05) with no significant difference in animals pretreated with propranolol. There was no significant difference in glycogen concentration (p>0.05) in animals infused with hexoses only compared with propanolol pretreated group. CONCLUSIONS: Results suggests that one of the possible fates of the enormous amount of glucose taken up by the intestine is conversion to lactate and not glycogen and ß-adrenergic receptor does not affect it.


Subject(s)
Blood Glucose , Glycogen , Adrenergic Agents , Animals , Dogs , Fructose , Galactose , Glucose , Insulin , Intestines , Lactic Acid , Male , Propranolol/pharmacology
11.
Eur J Pharm Biopharm ; 169: 12-19, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34508807

ABSTRACT

In preclinical drug development, ex vivo and in vitro permeability studies are a decisive element for specifying subsequent development steps. In this context, reliability, physiological alignment and appropriate in vivo correlation are mandatory for predictivity regarding drug absorption. Especially in oromucosal drug delivery, these prerequisites are not adequately met, which hinders its progressive development and results in the continuous need for animal experiments. To address current limitations, an innovative, standardized, and controlled ex vivo permeation model was applied. It is based on Kerski diffusion cells embedded in automated sampling and coupled to mass spectrometric quantification under physiologically relevant conditions. This study aimed to evaluate the predictivity of the developed model using porcine mucosa (ex vivo) in relation to data of sublingual propranolol absorption (in vivo). In addition, the usefulness of biomimetic barriers (in vitro) as a replacement for porcine mucosa was investigated. Therefore, solubility and permeability studies considering microenvironmental conditions were conducted and achieved good predictivity (R2 = 0.997) for pH-dependent permeability. A multiple level C correlation (R2 ≥ 0.860) between obtained permeability and reported pharmacokinetic animal data (AUC, Cmax) was revealed. Furthermore, a point-to-point correlation was demonstrated for several sublingual formulations. The successful IVIVC confirms the standardized ex vivo model as a viable alternative to animal testing for estimating the in vivo absorption behavior of oromucosal pharmaceuticals.


Subject(s)
Oral Mucosal Absorption/physiology , Propranolol/pharmacokinetics , Administration, Sublingual , Adrenergic beta-Antagonists/pharmacokinetics , Animals , Drug Development/methods , Drug Evaluation, Preclinical/methods , Models, Animal , Mouth Mucosa/physiology , Permeability , Swine
12.
Int J Mol Med ; 48(4)2021 Oct.
Article in English | MEDLINE | ID: mdl-34414453

ABSTRACT

The present study aimed to investigate the effect of ß­receptor blocker propranolol on early osseointegration of pure titanium implants and the underlying molecular regulatory mechanisms. An implant osseointegration model using the tibial metaphysis of New Zealand rabbits was established. The rabbits were divided into control and low­, medium­ and high­dose propranolol groups. The formation of implant osseointegration was detected by X­ray scanning. Mesenchymal stem cells (MSCs) and osteoblasts (OBs) were isolated and cultured in vitro, isoproterenol was supplemented to simulate sympathetic action and propranolol was subsequently administrated. The effect of propranolol on cell proliferation and osteogenic differentiation were assessed by EdU, flow cytometry, alizarin red staining and alkaline phosphatase (ALP) detection. The expression levels of bone morphogenetic protein (BMP)2, RUNX family transcription factor (RunX)2, collagen (COL)­1, osteocalcin (OCN) and ß2­adrenergic receptor (AR) were detected by immunofluorescence, reverse transcription­quantitative PCR and western blot assay. Propranolol effectively promoted implant osseointegration in vivo, facilitated proliferation of OBs, inhibited proliferation of MSCs and enhanced osteogenic differentiation of OBs and MSCs. The calcium content and ALP activity of cells treated with propranolol were markedly higher than in the control group. Propranolol also elevated mRNA and protein expression levels of BMP2, RunX2, COL­1 and OCN in tissue and cells, and decreased the expression of ß2­AR. The present study demonstrated that the ß­receptor blocker propranolol promoted osteogenic differentiation of OBs and MSCs and enhanced implant osseointegration. The present study provided a novel insight into the application and regulatory mechanisms of propranolol.


Subject(s)
Cell Differentiation/drug effects , Osseointegration/drug effects , Osteogenesis/drug effects , Propranolol/pharmacology , Animals , Bone Morphogenetic Protein 2/metabolism , Cell Proliferation/drug effects , Cells, Cultured , Core Binding Factor Alpha 1 Subunit/metabolism , Gene Expression Regulation/drug effects , Male , Mesenchymal Stem Cells/drug effects , Mesenchymal Stem Cells/metabolism , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteocalcin/drug effects , Osteocalcin/metabolism , Rabbits , Receptors, Adrenergic, beta-2/metabolism , Titanium/pharmacology
13.
J Complement Integr Med ; 18(4): 701-710, 2021 May 10.
Article in English | MEDLINE | ID: mdl-33962501

ABSTRACT

OBJECTIVES: Resveratrol as a natural polyphenolic agent can alleviate neuropathic pain symptoms. The mechanism of analgesic activity of resveratrol is far from clear. The current study examine whether analgesic activity of resveratrol is mediated by its neuroprotective and anti-oxidant activity in the neuropathic pain. We further examine whether analgesic activity of resveratrol is mediated by ß-adrenoceptors in the brain. METHODS: Neuropathic pain induced by L5 spinal nerve ligation (SNL). Male Wistar rats assigned into sham, SNL, SNL + resveratrol (40 µg/5 µL), and SNL + resveratrol + propranolol (a non-selective ß-adrenoceptor antagonist, 30 µg/5 µL) groups. Drugs injected intracerebroventricular (ICV) at day SNL surgery and daily for 6 days following SNL. Thermal allodynia and anxiety examined on days of -1, 2, 4, and 6 following SNL. Electrophysiological study performed on day 6 following SNL for evaluation of resveratrol effects on sciatic nerve conduction velocity (NCV). The activity of catalase (Cat) and superoxide dismutase (SOD) enzymes in the brain assessed on days 6 following SNL. RESULTS: Resveratrol significantly decreased thermal allodynia (and not anxiety) in all experimental days. Additionally, resveratrol significantly increased NCV, and also normalized the disrupted Cat and SOD activities following neuropathic pain. Furthermore, propranolol significantly blocked the analgesic and neuroprotective effects of resveratrol. CONCLUSIONS: It is suggested that the analgesic effects of resveratrol is mediated by its neuroprotective and antioxidant activities in the neuropathic rats. Furthermore, propranolol blocked the analgesic and neuroprotective effects of resveratrol.


Subject(s)
Neuroprotective Agents , Analgesics/pharmacology , Analgesics/therapeutic use , Animals , Disease Models, Animal , Hyperalgesia/drug therapy , Ligation , Male , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Propranolol/pharmacology , Rats , Rats, Sprague-Dawley , Rats, Wistar , Resveratrol , Spinal Nerves
14.
J Vasc Interv Radiol ; 32(2): 293-298, 2021 02.
Article in English | MEDLINE | ID: mdl-33221193

ABSTRACT

PURPOSE: To report the effectiveness and safety of transcatheter arterial sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas that did not respond appreciably to propranolol. MATERIALS AND METHODS: A total of 21 infants (12 male and 9 female) with large propranolol-resistant infantile hemangiomas in the parotid region were enrolled in this study. During TASE, the feeding arteries of the lesions were embolized using pingyangmycin-lipiodol emulsion and polyvinyl alcohol particles (300-500 µm) to reduce the blood flow rate. All children were followed up as outpatients at 2 weeks and monthly thereafter. The curative effect was evaluated at the 1- and 3-month follow-up visits. RESULTS: Nine lesions were located on the right side of the parotid gland, whereas 12 were located on the left side. The feeding arteries in all patients originated from branches of the external carotid artery. TASE was technically successful in all patients. The mean (± SD) maximal diameter of the hemangiomas significantly decreased from 6.50 cm ± 2.28 before treatment to 3.56 cm ± 1.84 at 1 month after TASE (P <. 05). Three months after TASE, the mean maximal diameter further significantly decreased to 1.94 cm ± 1.58 (P <. 05). During the follow-up period, 16 cases were rated as excellent and 5 as good; no recurrence or serious complications were noted. Minor side effects, such as slight pain, mild fever, and tissue swelling, were observed. CONCLUSIONS: TASE significantly decreased the size of the parotid hemangiomas with minor side effects during a short follow-up period.


Subject(s)
Antineoplastic Agents/therapeutic use , Drug Resistance, Neoplasm , Embolization, Therapeutic , Hemangioma/therapy , Parotid Neoplasms/therapy , Propranolol/therapeutic use , Sclerotherapy , Bleomycin/administration & dosage , Bleomycin/analogs & derivatives , Embolization, Therapeutic/adverse effects , Ethiodized Oil/administration & dosage , Female , Hemangioma/diagnostic imaging , Hemangioma/pathology , Humans , Infant , Male , Parotid Neoplasms/diagnostic imaging , Parotid Neoplasms/pathology , Polyvinyl Alcohol/administration & dosage , Sclerosing Solutions/administration & dosage , Sclerotherapy/adverse effects , Time Factors , Treatment Outcome , Tumor Burden
15.
Am J Kidney Dis ; 77(5): 704-712, 2021 05.
Article in English | MEDLINE | ID: mdl-33010357

ABSTRACT

RATIONAL & OBJECTIVE: Beta-blockers are recommended for patients with heart failure (HF) but their benefit in the dialysis population is uncertain. Beta-blockers are heterogeneous, including with respect to their removal by hemodialysis. We sought to evaluate whether ß-blocker use and their dialyzability characteristics were associated with early mortality among patients with chronic kidney disease with HF who transitioned to dialysis. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adults patients with chronic kidney disease (aged≥18 years) and HF who initiated either hemodialysis or peritoneal dialysis during January 1, 2007, to June 30, 2016, within an integrated health system were included. EXPOSURES: Patients were considered treated with ß-blockers if they had a quantity of drug dispensed covering the dialysis transition date. OUTCOMES: All-cause mortality within 6 months and 1 year or hospitalization within 6 months after transition to maintenance dialysis. ANALYTICAL APPROACH: Inverse probability of treatment weights using propensity scores was used to balance covariates between treatment groups. Cox proportional hazard analysis and logistic regression were used to investigate the association between ß-blocker use and study outcomes. RESULTS: 3,503 patients were included in the study. There were 2,115 (60.4%) patients using ß-blockers at transition. Compared with nonusers, the HR for all-cause mortality within 6 months was 0.79 (95% CI, 0.65-0.94) among users of any ß-blocker and 0.68 (95% CI, 0.53-0.88) among users of metoprolol at transition. There were no observed differences in all-cause or cardiovascular-related hospitalization. LIMITATIONS: The observational nature of our study could not fully account for residual confounding. CONCLUSIONS: Beta-blockers were associated with a lower rate of mortality among incident hemodialysis patients with HF. Similar associations were not observed for hospitalizations within the first 6 months following transition to dialysis.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Heart Failure/drug therapy , Hospitalization/statistics & numerical data , Kidney Failure, Chronic/therapy , Mortality , Renal Dialysis , Adrenergic beta-Antagonists/metabolism , Aged , Aged, 80 and over , Atenolol/metabolism , Atenolol/therapeutic use , Bisoprolol/metabolism , Bisoprolol/therapeutic use , Carvedilol/metabolism , Carvedilol/therapeutic use , Cause of Death , Cohort Studies , Female , Heart Failure/complications , Humans , Kidney Failure, Chronic/complications , Labetalol/metabolism , Labetalol/therapeutic use , Logistic Models , Male , Metoprolol/metabolism , Metoprolol/therapeutic use , Middle Aged , Nadolol/metabolism , Nadolol/therapeutic use , Proportional Hazards Models , Propranolol/metabolism , Propranolol/therapeutic use , Protective Factors , Retrospective Studies , Risk , Risk Factors
16.
Clin Exp Hypertens ; 43(1): 49-55, 2021 Jan 02.
Article in English | MEDLINE | ID: mdl-32706597

ABSTRACT

BACKGROUND: Lichens are a symbiotic association of a fungus with a green alga or cyanobacterium. They are widely used in traditional medicine as a treatment against skin disorders, diabetes and hypertension. THE AIM OF THE STUDY: The goal of this paper was to assess the possible antihypertensive and vasorelaxant capacity of the aqueous extract of a lichen species called Oakmoss or Evernia prunastri (L.). MATERIAL AND METHODS: In the present study, the aqueous extract of Oakmoss was prepared, its antihypertensive activity was examined in N(ω)-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats, and its vasorelaxant ability was performed in rat isolated thoracic aorta. RESULTS: The results proved that Oakmoss reduced the systolic, diastolic, mean arterial blood pressure, and heart rate in hypertensive rats but not in normotensive rats. Besides, the data showed that Oakmoss exerts its antihypertensive effect through vasorelaxant ability. CONCLUSION: The present study presents the favorable action of Oakmoss as an antihypertensive agent.


Subject(s)
Aorta, Thoracic/drug effects , Hypertension/physiopathology , Parmeliaceae , Plant Extracts/pharmacology , Adrenergic beta-Antagonists/pharmacology , Animals , Antihypertensive Agents/pharmacology , Arterial Pressure/drug effects , Blood Pressure/drug effects , Calcium Channel Blockers/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/toxicity , Glyburide/pharmacology , Hypertension/chemically induced , Hypertension/metabolism , KATP Channels/antagonists & inhibitors , Male , Methylene Blue/pharmacology , NG-Nitroarginine Methyl Ester/toxicity , Nifedipine/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Propranolol/pharmacology , Rats , Rats, Wistar , Resins, Plant , Terpenes , Vasodilator Agents/pharmacology
17.
J Clin Pharm Ther ; 46(1): 208-211, 2021 Feb.
Article in English | MEDLINE | ID: mdl-31913531

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Thyrotoxic periodic paralysis (TPP) with hypokalaemia is a rare acute phenomenon. Reports of the use of high-dose non-selective ß-blockers describe symptom resolution, but often administration does not occur promptly enough in the treatment course and patients may experience overcorrection and hyperkalaemia. CASE DESCRIPTION: A 37-year-old Hispanic male developed TPP. Patient was successfully treated with low-dose oral propranolol and potassium supplementation with no overcorrection. WHAT IS NEW AND CONCLUSION: Delay in the administration of non-selective ß-blockers may lead to overcorrection of potassium with exogenous supplementation. Low-dose propranolol administered in the Emergency Department was successful in preventing overcorrection of potassium.


Subject(s)
Anti-Arrhythmia Agents/administration & dosage , Hypokalemia/diagnosis , Paralysis/diagnosis , Propranolol/administration & dosage , Thyroid Crisis/diagnosis , Administration, Oral , Adult , Diagnosis, Differential , Emergency Service, Hospital , Humans , Hypokalemia/complications , Hypokalemia/drug therapy , Male , Paralysis/complications , Paralysis/drug therapy , Thyroid Crisis/complications , Thyroid Crisis/drug therapy
18.
J Pharm Sci ; 110(3): 1337-1348, 2021 03.
Article in English | MEDLINE | ID: mdl-33271137

ABSTRACT

Propranolol (PPL) administered orally is considered as the first line drug for the treatment of infantile hemangioma, however several systemic adverse effects limit its use. For this reason, our work tackles the development and evaluation of PPL loaded chitosan nanoparticles (NPs), as an effective alternative for the treatment of infantile hemangioma. PPL -NPs were prepared using the double emulsion technique and the influence of the formulation variables on drug entrapment efficiency (EE), particle size (PS), percent released after 24 h (%R24h) and zeta potential (ZP) were optimized using full factorial design. Two systems, namely F3 and F28 showing highest E.E., ZP and %R24h with lowest PS, were fully characterized for DSC and TEM and incorporated into hydrogel with adequate viscosity. After ensuring safety for the selected nanoparticle, the hydrogel containing the optimized system was applied topically to rats. The in-vivo skin deposition in rats showed an accumulation of propranolol from the lecithin/chitosan nanocarrier by 1.56-1.91-fold when compared to the drug solution. The obtained result was further supported by the confocal laser scanning microscopy which showed fluorescence across the skin. PPL-HCL-loaded lecithin/chitosan nanoparticles could be considered as a potential candidate for treating infantile hemangiomas (IH) by maintaining therapeutic concentration topically while minimizing systemic side effects.


Subject(s)
Chitosan , Nanoparticles , Animals , Drug Carriers , Lecithins , Particle Size , Propranolol , Rats , Skin Absorption
19.
Pak J Pharm Sci ; 33(3): 1033-1048, 2020 May.
Article in English | MEDLINE | ID: mdl-33191227

ABSTRACT

Curcuma was the dried rhizomes of Curcuma kwangsiensis S.G. Lee et C.F. Liang (Chinese name: e zhu), have been used in China for thousands of years. There are some reports have shown that curcumin, the major component of curcuma, has a good curative effect on psoriasis, but the mechanism is still unknown, so the present study was designed to investigate the effect of curcuma's extraction on psoriasis-like mouse, and to explore the mechanisms of therapy. First, we observed that curcuma's extractions effect on mitosis of mouse vaginal epithelial cells; then making psoriasis like model and measuring the score of skin damage on days 7 and 14; finally, we observed the expression of immune factors (CK14, CK16, CK17, PCNA, TLR-2, TLR-4, TLR-9) in propranolol induced psoriasis like rats. Curcuma's extraction prohibited the mitosis of mouse vaginal epithelial cells; curcuma's extractions have a significantly efficacy and dose dependent inhibition on imiquimod induced psoriasis like rats; and the expression of immune factors (CK14, CK16, CK17, PCNA, TLR-2, TLR-4, TLR-9) was decreasing in the curcuma's extraction treated groups compared with normal groups. Our research proved that curcuma's extractions have a significantly efficacy on psoriasis like rats, thus, curcuma's extractions can be a potential novel treatment for psoriasis. Furthermore, the expression of immune factors was decreasing after treatment with curcuma's extraction suggest us cytokines has strong relation with the mechanism of therapy for psoriasis. Our results contribute towards validation of curcuma in the treatment of psoriasis and other joint disorders.


Subject(s)
Curcuma , Dermatologic Agents/pharmacology , Keratins/metabolism , Plant Extracts/pharmacology , Proliferating Cell Nuclear Antigen/metabolism , Psoriasis/prevention & control , Skin/drug effects , Toll-Like Receptors/metabolism , Animals , Curcuma/chemistry , Dermatologic Agents/isolation & purification , Disease Models, Animal , Dose-Response Relationship, Drug , Epithelial Cells/drug effects , Epithelial Cells/pathology , Female , Guinea Pigs , Imiquimod , Male , Mice , Mitosis/drug effects , Plant Extracts/isolation & purification , Propranolol , Psoriasis/chemically induced , Psoriasis/metabolism , Psoriasis/pathology , Rhizome , Skin/metabolism , Skin/pathology , Time Factors , Vagina/drug effects , Vagina/pathology
20.
J Biomed Nanotechnol ; 16(4): 505-519, 2020 Apr 01.
Article in English | MEDLINE | ID: mdl-32970982

ABSTRACT

The clinical studies proved the adverse effect of Propranolol on sexual function. Regarding this issue, the key research question of this study was, whether the designed herbal nanohybrid formula EGCG-chitosan-alginate has an efficacy versus Propranolol, or not? The formula was optimized according to the coacervation method. Its molecular structure and characteristics were confirmed. The entrapment efficiency was determined, and the stability, as well in vitro release study was conducted. The in vivo study was conducted for 65 days. To answer the raised question, tissue weights of the testis, epididymis seminal vesicles, and prostate were determined. Oxidative stress markers as MDA and GSH were measured in testis and epididymis, while testosterone in blood serum. The semen analysis was performed. DNA damage was detected according to the comet assay procedures. Conventional pathological examination was done in special concern to testis and epididymis. The characterization results reflected the good preparation of the formula with an amorphous structure in a range of 200 nm, high stability with ZP + 57.3 mV. The calculated EE was 84.10 ± 1.19% and the release percent was 72.11 ± 0.77% for 24 hrs. All the rats increased in the weight with variations among the groups in the tissue organs. The finding exposed a significant decrease in the average of MDA in the rats' testes with a significant increase in GSH while a non-significant difference in the epididymis, in both. The testosterone, the seminal parameters, and the DNA integrity significantly increased in the nano-formula compared to propranolol. Likewise, normal pathological findings of the nano-formula in the testis and Epididymis compared to abnormal of propranolol. In total, the current research confirmed that EGCG had no toxic effects and able to promote fertility. The most important finding was the administration of EGCG either in normal or nano-form prior to propranolol alleviated the effects of propranolol. These findings reflected the protection evident of EGCG versus propranolol.


Subject(s)
Propranolol/chemistry , Sexual Dysfunction, Physiological , Adrenergic beta-Antagonists , Alginates , Animals , Catechin/analogs & derivatives , Chitosan , Male , Nanostructures , Organ Size , Rats
SELECTION OF CITATIONS
SEARCH DETAIL